Artisan Partners Highlights Guardant Health in Second-Quarter Mid Cap Fund Letter

CHICAGO — Artisan Partners Management Co. disclosed on Tuesday that Guardant Health Inc. remains a top holding in its Artisan Mid Cap Fund, as the investment firm released its second-quarter 2026 investor letter detailing portfolio performance and strategic positioning.

The disclosure, filed with regulatory authorities and distributed to fund shareholders, underscores the asset manager's continued conviction in the liquid biopsy sector despite a volatile year for healthcare equities. Guardant Health, which trades on the Nasdaq under the ticker GH, was identified as a significant component of the Mid Cap Fund's portfolio during the quarter ended June 30, 2026.

In the letter addressed to investors, Artisan Partners outlined the fund's performance metrics for the period, attributing specific returns to its concentrated positions in biotechnology and diagnostic firms. The firm noted that Guardant Health's market position as a leader in non-invasive cancer detection technologies aligns with the fund's long-term growth thesis. The investment manager cited the company's expanding commercial footprint and regulatory approvals in key international markets as primary drivers for maintaining the position.

The Artisan Mid Cap Fund, which focuses on companies with market capitalizations typically ranging between $2 billion and $10 billion, has faced scrutiny from analysts regarding its exposure to pre-profitability biotech firms. However, the firm's leadership defended the allocation in the quarterly missive, emphasizing the potential for Guardant Health to achieve profitability through cost-reduction initiatives and increased testing volume.

Market reaction to the disclosure was muted on Tuesday, with Guardant Health shares trading nearly flat ahead of the close. The stock has experienced significant volatility throughout 2026, influenced by broader sector headwinds and shifting investor sentiment toward high-risk healthcare assets. Artisan Partners did not disclose the exact percentage of the fund's net assets allocated to Guardant Health in the public letter, a standard practice for many institutional investors to avoid revealing precise trading strategies.

The release comes as the mid-cap equity sector navigates a complex macroeconomic environment characterized by fluctuating interest rates and evolving healthcare policy debates. Artisan Partners indicated that it would continue to monitor Guardant Health's quarterly earnings reports and clinical trial data closely before making further adjustments to its position.

Investors are now looking toward the upcoming third-quarter earnings season for more clarity on whether the fund will increase, decrease, or maintain its stake in the cancer diagnostics firm. The letter did not address potential risks associated with regulatory changes in the U.S. Food and Drug Administration's oversight of genomic testing, leaving questions about the long-term stability of the holding open as the market enters the final quarter of 2026.